Impact of Time to Treatment Initiation on Quality of Response in Patients with Acute Myeloid Leukemia Receiving Intensive Chemotherapy
This study suggests that a treatment delay of up to 14 days does not negatively impact OS or MRD negativity. This timeframe potentially allows for thorough patient evaluation, including detailed genetic profiling and comorbidity assessment, facilitating a more personalized and optimized therapeutic strategy.
Authors
- Francesco Buccisano (ORCID: https://orcid.org/0000-0003-4320-9253)
- Fabiana Esposito (ORCID: https://orcid.org/0000-0002-7305-7222)
- Giovangiacinto Paterno (ORCID: https://orcid.org/0000-0002-8944-0795)
- Lucrezia De Marchi
- Lucia Cardillo
- Ilaria Cerroni
- Luca Maurillo (ORCID: https://orcid.org/0000-0001-7297-4988)
- Flavia Mallegni
- Carmelo Gurnari (ORCID: https://orcid.org/0000-0001-6829-5544)
- Federico Moretti (ORCID: https://orcid.org/0000-0001-6730-5296)
- Raffaele Palmieri (ORCID: https://orcid.org/0000-0003-2855-8121)
- Elisa Meddi
- Elisa Buzzatti (ORCID: https://orcid.org/0000-0002-3478-5083)
- Marco Zomparelli
- Kristian Taka
- Maria Ilaria Del Principe
- Adriano Venditti (ORCID: https://orcid.org/0000-0002-0245-0553)
- Kleda Zaganjori
Institutions
- University of Rome Tor Vergata (IT)
- Cleveland Clinic (US)
- Policlinico Tor Vergata (IT)
Publication Details
- Journal
- Cancers
- Published
- 2025-06-18
- DOI
- https://doi.org/10.3390/cancers17122028
- Citations
- 1
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.77